NEW YORK -- Manhattan Scientifics, Inc. (MHTX) announced today that its Senior Scientific, LLC unit, developing a platform for the early detection of cancer and other human diseases, has renewed its Collaboration Agreement with The University of Texas MD Anderson Cancer Center, establishing a multi-year program with extended scope. The agreement calls for MD Anderson to participate in a rigorous development program to translate the pre-clinical research to first use in humans.
“We look forward to evaluating the potential of the MRX technology for early detection of ovarian cancer. If preliminary studies from Senior Scientific can be confirmed and extended, the technology could be transformative,” said Robert Bast, M.D., Vice President for Translational Research at MD Anderson. Added Dr. John Hazle, Chairman for the Department of Imaging Physics and Principle Investigator for the collaboration, “We are excited to renew and extend the collaboration with Senior Scientific. MD Anderson now will be committing significant resources across biology, chemistry and computational methods to work with Senior Scientific to make the MRX technology commercially ready.”
“The willingness of MD Anderson investigators to collaborate in this project underscores the potential medical value of our MRX technology,” said Bob Proulx, President and COO of Senior Scientific. “Our relationships with key cancer research institutes, like MD Anderson, will be important as we look to develop commercial partnerships to bring the MRX technology into diagnostic use.”
Senior Scientific LLC (http://www.seniorscientific.com) is at the crossroads of biotechnology and nanotechnology. Our novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. Senior Scientific is owned by Manhattan Scientifics, Inc., a publicly traded company dedicated to assisting scientific enterprises commercialize transformative new technologies.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on commercialization of disruptive technologies in the nano medicine space.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.